REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 82.50
Bid: 80.00
Ask: 85.00
Change: 0.00 (0.00%)
Spread: 5.00 (6.25%)
Open: 82.50
High: 82.50
Low: 82.50
Prev. Close: 82.50
FDBK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Total Voting Rights

1 Nov 2022 15:36

RNS Number : 9670E
Feedback PLC
01 November 2022
 

Feedback plc

 

Total Voting Rights

 

London, 1 November 2022 Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces in conformity with the FCA's Disclosure Guidance and Transparency Rule 5.6.1, that as at 31 October 2022, the Company's total issued share capital consisted of 13,334,659 ordinary shares of 50 pence each with one voting right per share. The Company does not hold any ordinary shares in Treasury. Therefore, the total number of voting rights in the Company is 13,334,659.

 

The above figure of 13,334,659 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 

-Ends-

 

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Anesh Patel, CFO

+44 (0) 20 3997 7634

IR@fbk.com

 

Panmure Gordon (UK) Limited (NOMAD and Broker)

Emma Earl/Freddy Crossley (Corporate Finance)

Rupert Dearden (Corporate Broking)

+44 (0)20 7886 2500

 

Walbrook PR Ltd;

Tel: 020 7933 8780 or feedbackplc@walbrookpr.com

Paul McManus/Nick Rome

07980 541 893 or 07748 325 236 or 07884 664 686

 

 

About Feedback

 

Feedback plc helps clinical teams to make better decisions faster for patients. We design products that enhance clinician access to patient data and to their colleagues. Our unique approach centres around individual patient episodes, into which we pull relevant clinical data from hospital systems and around which we build remote clinical teams for collaboration. As a result, we produce a digital infrastructure that makes patient data available to clinicians in multiple settings, in a format that enables them to meaningfully interact with it, providing flexibility to clinicians and free movement of patients between provider settings - clinicians can practice from anywhere and patients can attend any care provider for treatment.

 

Our products Bleepa and CareLocker work together to deliver unparalleled value to our customers. Bleepa is our application layer and sits on top of CareLocker as our data layer. Bleepa is a clinician facing platform that displays clinical results from a patient's CareLocker at a certified and regulated quality, that is suitable for clinical use and enables dialogue on a patient-by-patient basis with colleagues through a secure, auditable chat interface that links back to the patient medical record. The CareLocker data storage model is built around the patient. Our vision is one where relevant clinical data is always available to the patient as well as to any care setting that they may attend - a federated data architecture with the patient as the tenant.

 

The Company has a number of growth opportunities domestically and internationally across a range of markets including the NHS, the veterinary market and private healthcare providers and its highly scalable Software as a Service ("SaaS")-based revenue model is expected to provide increasing levels of visibility as the Company grows its customer base.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRUAOVRUVUARAA
Date   Source Headline
19th Dec 20062:36 pmRNSInterim Results
19th Oct 20063:46 pmRNSHolding(s) in Company
17th Oct 20069:53 amRNSDirector/PDMR Shareholding
28th Sep 20065:25 pmRNSPosting of accounts
27th Sep 20067:01 amRNSFinal Results
18th Apr 20064:55 pmRNSHolding(s) in Company
21st Feb 20061:04 pmRNSHolding(s) in Company
17th Jan 20068:28 amRNSHolding(s) in Company
14th Dec 20057:01 amRNSInterim Results
30th Nov 20052:34 pmRNSHolding(s) in Company
23rd Sep 20052:53 pmRNSConversion of Securities
10th Aug 20057:01 amRNSFinal Results
21st Jul 20055:06 pmRNSHolding(s) in Company
11th Jul 20055:21 pmRNSConversion of Securities
14th Apr 200512:23 pmRNSConversion of Securities
16th Mar 20051:07 pmRNSDisposal
28th Feb 20055:04 pmRNSCirc re. EGM
24th Feb 200512:49 pmRNSStatement re Pension Scheme

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.